Hepion Pharmaceuticals Receives Positive FDA Response on GV104 in Gambling Disorder, a Condition With No Approved Medication

(OTCQB:HEPA) ("Hepion" or the "Company"), a biotechnology company developing a portfolio of diagnostic and therapeutic candidates for serious liver, immune, and inflammatory diseases, today announced ...

Aquestive: FDA Acceptance Of Anaphylm Resubmission Makes For Rating Upgrade

Aquestive Therapeutics is upgraded to a Buy, anticipating Anaphylm approval and potential >$250m annual revenue by 2030. Click to read more on AQST.
Sidley Austin LLP

Sidley Represents Aquestive Therapeutics in Exclusive U.S. Licensing Agreement With Eton Pharmaceuticals

Sidley represented Aquestive Therapeutics, Inc. (Nasdaq: AQST) in an exclusive license agreement and a supply agreement with Eton Pharmaceuticals, Inc. (Nasdaq: ETON) for Libervant® (diazepam) buccal ...